A topological substructural approach for the prediction of P-glycoprotein substrates

Journal of Pharmaceutical Sciences

Volumn 95, Issue 3, 2006, Pages 589-606

  Cabrera, Miguel Angel ^a   González, Isabel ^b   Fernández, Carlos ^b   Navarro, Carmen ^b   Bermejo, Marival ^b  

^a CENTRAL UNIVERSITY OF LAS VILLAS   (Cuba)

^b UNIVERSITY OF VALENCIA   (Spain)

Author keywords

In silico; Molecular modeling; P glycoprotein; P gp; QSAR; TOPS MODE

Indexed keywords

CHEMICAL COMPOUND; GLYCOPROTEIN P; INDOMETACIN; NALOXONE; NALTREXONE; NORFLOXACIN; PAZUFLOXACIN; QUINOLONE DERIVATIVE; SALAZOSULFAPYRIDINE;

ARTICLE; DRUG MARKETING; ELECTRICITY; EXTERNAL VALIDITY; MOLECULAR MODEL; POLARIZATION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; SENSITIVITY AND SPECIFICITY; STATISTICAL MODEL;

EID: 33645357793     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.20449     Document Type: Review

References (61)

1. Schinkel AH. 1999. P-Glycoprotein, a gatekeeper in the blood-brain barrier. Adv Drug Deliver Rev 36:179-194.
2. Kim RB, Fromm MF, Wandel C, Leake B, Wood AJ, Roden DM, Wilkinson GR. 1998. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 101:289-294.
3. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS. 2001. Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther 299:620-628.
4. Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J. 2003. Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem 46:1716-1725.
5. Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW. 2002. Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther 303:1029-1037.
6. Stouch TR, Gudmundsson O. 2002. Progress in understanding the structure-activity relationships of P-glycoprotein. Adv Drug Deliv Rev 54:315-328.
7. Xue Y, Yap CW, Sun LZ, Cao ZW, Wang JF, Chen YZ. 2004. Prediction of P-Glycoprotein Substrates by a Support Vector Machine Approach. J Chem Inf Comput Sci 44:1497-1505.
8. Ekins S, Waller CL, Swaan PW, Cruciani G, Wrighton SA, Wikel JH. 2000. Progress in predicting human ADME parameters in silico. J Pharmacol Toxicol Methods 44:251-272.
9. Zhang EY, Phelps MA, Cheng C, Ekins S, Swaan PW. 2002. Modeling of active transport systems. Adv Drug Deliv Rev 54:329-354.
10. Gombar VK, Polli JW, Humphreys JE, Wring SA, Serabjit-Singh CS. 2004. Predicting P-glycoprotein substrates by a quantitative structure-activity relationship model. J Pharm Sci 93:957-968.
11. Estrada E. 2000. On the topological sub-structural molecular design (TOSS-MODE) in QSPR/QSAR and drug design research. SAR QSAR Environ Res 11:55-73.
12. Cabrera MA, Gonzalez H, Fernandez C, Pla-Delfina JM, Bermejo M. 2002. A novel approach to determining physicochemical and absorption properties of 6-fluoroquinolone derivatives: experimental assessment. Eur J Pharm Biopharm 53:317-325.
13. Cabrera MA, Ruiz A, FernÃndez C, González I, Bermejo M. 2003. A topological-substructural molecular design (TOPS-MODE) approach to determining pharmacokinetics and pharmacological properties of 6-fluoroquinolone derivatives. Eur J Pharm Biopharm 56:197-206.
14. Cabrera MA, Bermejo M, Perez M, Ramos R. 2004. TOPS-MODE approach for the prediction of blood-brain barrier permeation. J Pharm Sci 93:1701-1717.
15. Gonzalez MP, Diaz HG, Cabrera MA, Ruiz RM. 2004. A novel approach to predict a toxicological property of aromatic compounds in the Tetrahymena pyriformis. Bioorg Med Chem 12:735-744.
16. Cabrera MA, Bermejo M, Ramos L, Grau R, Pérez M, González H. 2004. A topological sub-structural approach for predicting human intestinal absorption of drugs. Eur J Med Chem 39:905-916.
17. Cabrera MA, Bermejo M. 2004. In silico prediction of central nervous system activity of compounds. Identification of potential pharmacophores by the TOPS-MODE approach. Bioorg Med Chem 12:5833-5843.
18. Estrada E, Uriarte E, Montero A, Teijeira M, Santana L, De Clercq E. 2000. A novel approach for the virtual screening and rational design of anticancer compounds. J Med Chem 43:1975-1985.
19. Estrada E, Pena A. 2000. In silico studies for the rational discovery of anticonvulsant compounds. Bioorg Med Chem 8:2755-2770.
20. Estrada E, Vilar S, Uriarte E, Gutierrez Y. 2002. In silico studies toward the discovery of new anti-HIV nucleoside compounds with the use of TOPS-MODE and 2D/3D connectivity indices. 1. Pyrimidyl derivatives. J Chem Inf Comput Sci 42:1194-1203.
21. Estrada E, Uriarte E, Gutierrez Y, Gonzalez H. 2003. Quantitative structure-toxicity relationships using TOPS-MODE. 3. Structural factors influencing the permeability of commercial solvents through living human skin. SAR QSAR Environ Res 14:145-163.
22. Estrada E, Patlewicz G, Gutierrez Y. 2004. From knowledge generation to knowledge archive. A general strategy using TOPS-MODE with DEREK to formulate new alerts for skin sensitization. J Chem Inf Comput Sci 44:688-698.
23. Wang R, Gao Y, Lai L. 2000. Calculating partition coefficient by atom-additive method. Perspect Drug Discov Des 19:47-66.
24. Ertl P, Rohde B, Selzer P. 2000. Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. J Med Chem 43:3714-3717.
25. Miller KJ. 1990. Additivity methods in molecular polarizability. J Am Chem Soc 112:8533-8542.
26. Gasteiger J, Marsilli M. 1978. A new model for calculating atomic charge in molecules. Tetrahedron Lett 34:3181-3184.
27. Bondi A. 1964. van der Waals volumes and radii. J Phys Chem 68:441-451.
28. Ghose AK, Crippen GM. 1987. Atomic physicochemical parameters for three-dimensional-structure-directed quantitative structure-activity relationships. 2. Modeling dispersive and hydrophobic interactions. J Chem Inf Comput Sci 27:21-35.
29. Ferguson LN. 1963. The modern structural theory of organic chemistry, edn. Englewoods Cliffs: Prentice-Hall.
30. Potapov VM. 1978. Stereochemistry, edn. Moscow: MIR.
31. Gutierrez Y, Estrada E. 2002. MODESLAB 1.0 (Molecular DEScriptors LABoratory) for Windows.
32. Weininger D. 1988. SMILES, a chemical language and information system. 1. Introduction to methodology and encoding rules. J Chem Inf Comput Sci 28:31-36.
33. Seelig A. 1998. A general pattern for substrate recognition by P-glycoprotein. Eur J Biochem 251:252-261.
34. Penzotti JE, Lamb ML, Evensen E, Grootenhuis PD. 2002. A computational ensemble pharmacophore model for identifying substrates of P-glycoprotein. J Med Chem 45:1737-1740.
35. StatSoft. 1999. STATISTICA version 5.5 for Windows, StatSoft, Inc.
36. Walker JD, Carlsen L, Jaworska J. 2003. Improving opportunities for regulatory acceptance of QSARs: the importance of model domain, uncertainty, validity and predictability. QSAR Comb Sci 22:346-350.
37. Eriksson L, Jaworska J, Worth AP, Cronin MT, McDowell RM, Gramatica P. 2003. Methods for reliability and uncertainty assessment and for applicability evaluations of classification- and regression-based QSARs. Environ Health Perspect 111:1361-1375.
38. Randic M. 1991. Resolution of ambiguities in structure-property studies by us of orthogonal descriptors. J Chem Inf Comput Sci 31:311-320.
39. Randic M. 1991. Orthogonal molecular descriptors. New J Chem 15:517-525.
40. Randic M. 1991. Correlation of enthalpy of octanes with orthogonal connectivity indices. J Mol Struct (Teochem) 233:45-59.
41. Estrada E, Perdomo-Lopez I, Torres-Labandeira JJ. 2001. Combination of 2D-, SD-connectivity and quantum chemical descriptors in QSPR. Complexation of alpha- and beta-cyclodextrin with benzene derivatives. J Chem Inf Comput Sci 41:1561-1568.
42. Randic M. 1993. Fitting of Nonlinear Regressions by Orthogonalized Power Series. J Comput Chem 4:363-370.
43. Callaghan R, Riordan JR. 1995. Collateral sensitivity of multidrug resistant cells to narcotic analgesics is due to effects on the plasma membrane. Biochim Biophys Acta 1236:155-162.
44. McNicholas JM. 2004. Inhibitors of abc drug transporters in microbial cells. USA: US Patent & Trademark Office.
45. Perloff MD, Stormer E, von Moltke LL, Greenblatt DJ. 2003. Rapid assessment of P-glycoprotein inhibition and induction in vitro. Pharm Res 20:1177-1183.
46. Liang E, Proudfoot J, Yazdanian M. 2000. Mechanisms of transport and structure-permeability relationship of sulfasalazine and its analogs in Caco-2 cell monolayers. Pharm Res 17:1168-1174.
47. Bradley M, Waller CL. 2001. Polarizability fields for use in three-dimensional quantitative structure-activity relationship (3D-QSAR). J Chem Inf Comput Sci 41:1301-1307.
48. Hansch C, Steinmetz WE, Leo AJ, Mekapati SB, Kurup A, Hoekman D. 2003. On the role of polarizability in chemical-biological interactions. J Chem Inf Comput Sci 43:120-125.
49. Osterberg T, Norinder U. 2000. Theoretical calculation and prediction of P-glycoprotein-interacting drugs using MolSurf parametrization and PLS statistics. Eur J Pharm Sci 10:295-303.
50. Seelig A, Landwojtowicz E, Fischer H, Blatter XL. 2003. Towards P-glycoprotein structure-activity relationships. In: Waterbeemd Hvd, Lennernas H, Artursson P, editors. Drug bioavailability/estimation of solubility, permeability, absorption and bioavailability. Weinheim: Wiley-VCH Verlag GmbH & Co. KGaA. pp 461-492.
51. Estrada E. 1997. Spectral moments of the edge-adjacency matrix of molecular graphs. 2. Molecules containing heteroatoms and QSAR applications. J Chem Inf Comput Sci 37:320-328.
52. Burkert U, Allinger NL. 1982. Molecular Mechanics, edn. Washington, DC: American Chemical Society.
53. Lin JH. 2004. How significant is the role of P-glycoprotein in drug absorption and brain uptake? Drugs Today (Barc) 40:5-22.
54. Dautrey S, Felice K, Petiet A, Lacour B, Carbon C, Farinotti R. 1999. Active intestinal elimination of ciprofloxacin in rats: modulation by different substrates. Br J Pharmacol 127:1728-1734.
55. de Lange EC, Marchand S, van den Berg D, van der Sandt IC, de Boer AG, Delon A, Bouquet S, Couet W. 2000. In vitro and in vivo investigations on fluoroquinolones; effects of the P-glycoprotein efflux transporter on brain distribution of sparfloxacin. Eur J Pharm Sci 12:85-93.
56. Yamaguchi H, Yano I, Hashimoto Y, Inui KI. 2000. Secretory mechanisms of grepafloxacin and levofloxacin in the human intestinal cell line caco-2. J Pharmacol Exp Ther 295:360-366.
57. Naruhashi K, Tamai I, Inoue N, Muraoka H, Sai Y, Suzuki N, Tsuji A. 2001. Active intestinal secretion of new quinolone antimicrobials and the partial contribution of P-glycoprotein. J Pharm Pharmacol 53:699-709.
58. Cormet-Boyaka E, Huneau JF, Mordrelle A, Boyaka PN, Carbon C, Rubinstein E, Tome D. 1998. Secretion of sparfloxacin from the human intestinal Caco-2 cell line is altered by P-glycoprotein inhibitors. Antimicrob Agents Chemother 42:2607-2611.
59. Rabbaa L, Dautrey S, Colas-Linhart N, Carbon C, Farinotti R. 1997. Absorption of ofloxacin isomers in the rat small intestine. Antimicrob Agents Chemother 41:2274-2277.
60. Shimizu A, Miyoshi M, Sugie M, Ueyama J, Yamaguchi T, Sasaki T, Takagi K, Jin M, Miyamoto K, Tsuji A, Hasegawa T. 2004. Possible involvement of P-glycoprotein in renal excretion of pazufloxacin in rats. Eur J Pharmacol 501:151-159.
61. Ruiz-Garcia A, Lin H, Pla-Delfina JM, Hu M. 2002. Kinetic characterization of secretory transport of a new ciprofloxacin derivative (CNV97100) across Caco-2 cell monolayers. J Pharm Sci 91:2511-2519.